Open AccessRepurposing dasatinib for diffuse large B cell lymphoma
Author(s) -
Claudio Scuoppo,
Jiguang Wang,
Mirjana Persaud,
Sandeep K. Mittan,
Katia Basso,
Laura Pasqualucci,
Raúl Rabadán,
Giorgio Inghirami,
Carla Grandori,
Francesc Bosch,
Riccardo DallaFavera
Publication year - 2019
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1905239116
Subject(s) - dasatinib , diffuse large b cell lymphoma , repurposing , lymphoma , cancer research , medicine , biology , imatinib , myeloid leukemia , ecology
Significance Novel therapies are needed for ∼40% of patients with diffuse large B cell lymphoma (DLBCL) who do not respond to standard immunochemotherapy. Here we show that dasatinib, a drug used in B cell acute lymphoblastic leukemia and chronic myelogenous leukemia, may be repositioned for DLBCL therapy and combined with mTORC2 inhibitors for resistant cases. Our results can provide the basis for clinical trials using dasatinib for DLBCL as well as other lymphoid malignancies, which depend on cellular pathways targeted by dasatinib.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom